Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms

Objective—Nicotinic acid (NA) treatment has been associated with benefits in atherosclerosis that are usually attributed to effects on plasma lipoproteins. The NA receptor GPR109A is expressed in monocytes and macrophages, suggesting a possible additional role for NA in modulating function of these immune cells. We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo. Methods and Results—In human monocytes activated by Toll-like receptor (TLR)-4 agonist lipopolysaccharide, NA reduced secretion of proinflammatory mediators: TNF-&agr; (by 49.2±4.5%); interleukin-6 (by 56.2±2.8%), and monocyte chemoattractant protein-1 (by 43.2±3.1%) (P<0.01). In TLR2 agonist, heat-killed Listeria monocytogenes-activated human monocytes, NA reduced secretion of TNF-&agr; (by 48.6±7.1%), interleukin-6 (by 60.9±1.6%), and monocyte chemoattractant protein-1 (by 59.3±5.3%) (P<0.01; n=7). Knockdown of GPR109A by siRNA resulted in a loss of this anti-inflammatory effect in THP-1 monocytes. However, inhibition of prostaglandin D2 receptor by MK0524 or COX2 by NS398 did not alter the anti-inflammatory effects of NA observed in activated human monocytes. Preincubation of THP-1 monocytes with NA 0.1 mmol/L reduced phosphorylated IKK&bgr; by 42±2% (P<0.001) IKB-&agr; by 54±14% (P<0.01). Accumulation of nuclear p65 NF-&kgr;B in response to lipopolysaccharide treatment was also profoundly inhibited, by 89±1.3% (n=4; P<0.01). NA potently inhibited monocyte adhesion to activated HUVEC, and VCAM, mediated by the integrin, very late antigen 4. Monocyte chemotaxis was also significantly reduced (by 45.7±1.2%; P<0.001). Conclusion—NA displays a range of effects that are lipoprotein-independent and potentially antiatherogenic. These effects are mediated by GPR109A and are independent of prostaglandin pathways. They suggest a rationale for treatment with NA that is not dependent on levels of plasma cholesterol and possible applications beyond the treatment of dyslipidemia.

[1]  G. Douglas,et al.  Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: Rational design through target quantification , 2011, Atherosclerosis.

[2]  I. Tabas,et al.  The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis , 2011, European journal of immunology.

[3]  S. Offermanns,et al.  Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. , 2011, The Journal of clinical investigation.

[4]  A. Davies,et al.  Unexpected protective role for Toll-like receptor 3 in the arterial wall , 2011, Proceedings of the National Academy of Sciences.

[5]  S. Tunaru,et al.  Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. , 2010, The Journal of clinical investigation.

[6]  P. Barter,et al.  Evidence That Niacin Inhibits Acute Vascular Inflammation and Improves Endothelial Dysfunction Independent of Changes in Plasma Lipids , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[7]  O. Dyar,et al.  Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin , 2010, Atherosclerosis.

[8]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[9]  A. Davies,et al.  Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis , 2009, Circulation.

[10]  M. Robson,et al.  Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[11]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[12]  R. Choudhury,et al.  Nicotinic acid and the prevention of coronary artery disease. , 2009, Current opinion in lipidology.

[13]  R. Pasternak,et al.  Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. , 2009, The American journal of cardiology.

[14]  J. Violin,et al.  beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. , 2009, The Journal of clinical investigation.

[15]  S. Offermanns,et al.  Niacin stimulates adiponectin secretion through the GPR109A receptor. , 2009, American journal of physiology. Endocrinology and metabolism.

[16]  Lin-hua Zhang,et al.  Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. , 2009, Atherosclerosis.

[17]  C. Ballantyne,et al.  Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. , 2008, The American journal of cardiology.

[18]  M. Fey,et al.  Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A) , 2008, Cell Death and Differentiation.

[19]  A. Waller,et al.  Regulation of Cell Adhesion by Affinity and Conformational Unbending of α4β1 Integrin1 , 2007, The Journal of Immunology.

[20]  Paul Y. Liu,et al.  Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. , 2007, Atherosclerosis.

[21]  D. Connolly,et al.  Langerhans cells release prostaglandin D2 in response to nicotinic acid. , 2006, The Journal of investigative dermatology.

[22]  A. Harris,et al.  Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. , 2006, Biochemical pharmacology.

[23]  D. Greaves,et al.  Mechanisms of Disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis , 2005, Nature Clinical Practice Cardiovascular Medicine.

[24]  M. Pichavant,et al.  Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response , 2005, European journal of immunology.

[25]  D. Greaves,et al.  Broad-Spectrum CC-Chemokine Blockade by Gene Transfer Inhibits Macrophage Recruitment and Atherosclerotic Plaque Formation in Apolipoprotein E–Knockout Mice , 2004, Circulation.

[26]  M. Trottmann,et al.  Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. , 2004, Biochemical pharmacology.

[27]  H. Matsushime,et al.  Molecular identification of nicotinic acid receptor. , 2003, Biochemical and biophysical research communications.

[28]  S. Tunaru,et al.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.

[29]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[30]  G. Hansson,et al.  Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation , 2002, Circulation.

[31]  M. Fishbein,et al.  Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL , 2001, Circulation.

[32]  M. Cybulsky,et al.  Adhesion of Monocytes to Arterial Endothelium and Initiation of Atherosclerosis Are Critically Dependent on Vascular Cell Adhesion Molecule-1 Gene Dosage , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[33]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[34]  J. Egido,et al.  Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. , 1999, Atherosclerosis.

[35]  M. Rothe,et al.  Bacterial Lipopolysaccharide Activates Nuclear Factor-κB through Interleukin-1 Signaling Mediators in Cultured Human Dermal Endothelial Cells and Mononuclear Phagocytes* , 1999, The Journal of Biological Chemistry.

[36]  A. Goldberg,et al.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.

[37]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[38]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[39]  T. Springer,et al.  The integrin VLA-4 supports tethering and rolling in flow on VCAM-1 , 1995, The Journal of cell biology.

[40]  T. Libermann,et al.  Activation of interleukin-6 gene expression through the NF-kappa B transcription factor , 1990, Molecular and cellular biology.

[41]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[42]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[43]  L. Carlson,et al.  INITIAL DISTRIBUTION IN MICE OF 3H-LABELED NICOTINIC ACID STUDIED WITH AUTORADIOGRAPHY. , 1964, Life sciences.